Tezepelumab NAVIGATOR trial in severe, uncontrolled asthma patients meets primary endpoint
NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) over
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.